Starling Oncology (STLNW) Asset Writedowns and Impairment (2021 - 2025)

Starling Oncology (STLNW) has reported Asset Writedowns and Impairment for 4 consecutive years, with -$2.4 million the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to -$2.4 million; the trailing twelve-month figure through Dec 2025 stood at -$2.4 million (changed N/A YoY), and the FY2025 full-year result was $2.4 million, changed N/A from the prior year.
• Asset Writedowns and Impairment fell to -$2.4 million in Q2 2025 per STLNW's latest filing, from $2.0 million in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q4 2023 and bottomed at -$2.4 million in Q2 2025.
• Historically, Asset Writedowns and Impairment has averaged -$26583.3 across 4 years, with a median of $64500.0 in 2021.
• The widest YoY moves for Asset Writedowns and Impairment: up 2587.84% in 2023, down 102.86% in 2023.
• Over 4 years, Asset Writedowns and Impairment stood at $250000.0 in 2021, then slumped by 70.4% to $74000.0 in 2022, then surged by 2587.84% to $2.0 million in 2023, then slumped by 220.56% to -$2.4 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered -$2.4 million, $2.0 million, and $33000.0 for Q2 2025, Q4 2023, and Q3 2023 respectively.